Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Kontafarma China Holdings Ltd ( (HK:1312) ) has shared an update.
Kontafarma China Holdings has warned that it expects to report a sharply wider consolidated net loss of about HK$414.1 million to HK$506.2 million for 2025, compared with a HK$99 million loss a year earlier. The deterioration is driven mainly by hefty impairment charges tied to its fitness operations, including expected credit losses, write-downs of intangible assets and substantial goodwill impairments in the fitness segment.
The bulk of these impairments stem from the cessation of franchise fitness operations in Taiwan run by associate True Concept Ltd and from the slower-than-expected recovery and intensifying competition facing the group’s Singapore fitness business. With True Concept’s centers shut since October 2025 and potential winding-up proceedings still pending, the announcement signals ongoing pressure on Kontafarma’s regional fitness strategy and underscores heightened risk for shareholders as they await audited 2025 results due by end-March 2026.
The most recent analyst rating on (HK:1312) stock is a Hold with a HK$0.03 price target. To see the full list of analyst forecasts on Kontafarma China Holdings Ltd stock, see the HK:1312 Stock Forecast page.
More about Kontafarma China Holdings Ltd
Kontafarma China Holdings Ltd is a Hong Kong-listed company with a diversified portfolio that includes a fitness business operating in markets such as Taiwan and Singapore. The group has used franchise and associate structures, including a 29% indirect stake in Taiwan-based True Concept Ltd, to expand its presence in the regional fitness industry.
Average Trading Volume: 1,182,033
Technical Sentiment Signal: Sell
Current Market Cap: HK$156.2M
For an in-depth examination of 1312 stock, go to TipRanks’ Overview page.